肱骨近端同种异体骨-假体复合重建的早期结果在5年随访时能否维持?
21例肱骨近端肿瘤切除后行同种异体骨-假体复合重建的患者中,6例失访被排除,植入物翻修的5年累积风险为10.1%(95%CI 1.6%-28.0%),MSTS评分从1年的86%降至5年的78%(平均差9%±14%,p=0.015),但主动前屈上举从101°降至92°无显著差异(p=0.41)。
要点
- 5年植入物翻修累积风险为10.1%(95%CI 1.6%-28.0%),以患者死亡为竞争风险。
- MSTS评分从1年86%降至5年78%(平均差9%±14%,p=0.015)。
- 12/21例出现>12个月随访时影像学上移>1cm,10/21例延迟愈合>12个月。
核心结论
- 在中期5年随访时,肱骨近端同种异体骨-假体复合重建具有可接受的总体MSTS评分和较低的植入物翻修发生率。
- 患者失访和排除出研究可能使结果看起来比实际情况更好。
- MSTS评分在1至5年间恶化,主动前屈上举下降不太可能是MSTS评分恶化的唯一原因。
- 包括延迟愈合、大结节吸收和上移在内的多种迟发并发症频繁发生,可能对总体评分有影响。
研究设计与样本
- 2000年至2015年间,21例患者因肱骨近端肿瘤切除后接受同种异体骨-假体复合重建。
- 6例失访患者未纳入分析;所有患者均为恶性或侵袭性良性肿瘤,可采用保留三角肌、腋神经和肩胛盂的广泛关节内入路。
- 以患者死亡为竞争风险计算植入物翻修的累积发生率;最短随访24个月(1例患者于22个月死亡例外),中位随访97个月(范围20-198个月)。
主要发现
- 植入物翻修的5年累积风险为10.1%(95%CI 1.6%-28.0%)。
- 平均MSTS评分1年为86%(±SD 9%),5年为78%(±SD 13%),平均差±SD 9%±14%,p=0.015。
- 平均主动前屈上举1年为101°(±SD 33°),5年为92°(±SD 34°),平均差±SD 8°±36°,p=0.41。
- 12个月随访后影像学上移>1cm见于21例中的12例,延迟愈合>12个月见于21例中的10例,大结节吸收见于21例中的9例,无菌性松动见于21例中的3例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 患者失访和排除出研究可能使结果看起来比实际情况更好。
- 未来比较同种异体骨-假体复合物与其他重建形式的研究应尝试控制可能的选择偏倚,并具有足够长的随访以检测随时间发生的MSTS评分恶化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Insufficiency of the rotator cuff is a major problem after resections of proximal humeral tumors and can limit shoulder motion despite preservation of the deltoid muscle and axillary nerve. Allograft-prosthetic composite reconstruction offers one method to reattach the rotator cuff tendons and has been successful in small studies with short followup. However, data are lacking with regard to implant durability, changes in Musculoskeletal Tumor Society (MSTS) scores over time, and delayed complications with extended followup. QUESTIONS/PURPOSES: (1) What is the cumulative incidence of allograft-prosthetic composite revision surgery 5 years after the procedure? (2) What are the early- and intermediate-term MSTS scores of allograft-prosthetic composite reconstruction of the shoulder? (3) What are the complications of allograft-prosthetic composite reconstruction? METHODS: Twenty-one patients underwent allograft-prosthetic composite reconstruction after tumor resection of the proximal humerus between 2000 and 2015. Six patients who were lost to followup were not included. All patients had malignant or aggressive benign tumors that could be treated with a wide intraarticular approach preserving the deltoid muscle, axillary nerve, and glenoid. Cumulative incidence of implant revision was calculated with death of the patient as a competing risk. Minimum followup was 24 months (with the exception of one patient who died at 22 months), and median followup was 97 months (range, 20-198 months). The upper extremity MSTS score was used to assess function. Various complications were identified from radiographs and charts. RESULTS: The cumulative risk of implant revision was 10.1% at 5 years (95% confidence interval [CI], 1.6%-28.0%). Mean MSTS scores were 86% (± SD 9%) at 1 year and 78% (± SD 13%) at 5 years (mean difference ± SD 9% ± 14%, p = 0.015). Mean active forward elevation was 101° (± SD 33°) at 1 year and 92° (± SD 34°) at 5 years (mean difference ± SD 8° ± 36°, p = 0.41). Notable adverse events included progressive radiographic superior subluxation > 1 cm after 12 months followup (12 of 21 patients), delayed union > 12 months (10 of 21 patients), resorption of the greater tuberosity (nine of 21 patients), and aseptic loosening (three of 21 patients). CONCLUSIONS: At intermediate 5-year followup, allograft-prosthetic composite reconstruction of the proximal humerus has an acceptable overall MSTS score and a low incidence of implant revision, but loss of patients to followup and exclusion from the study likely make the results seem better than they actually are. The MSTS score deteriorates between 1 and 5 years. Decreased active forward elevation is not likely to be the sole reason for worsening MSTS scores. A variety of delayed complications including delayed union, resorption of the greater tuberosity, and superior subluxation occurs frequently and may contribute to overall scores. Future studies that compare allograft-prosthetic composites against other forms of reconstruction should attempt to control for possible selection bias and have sufficiently long followup to detect the deterioration of MSTS scores that occur with time. LEVEL OF EVIDENCE: Level IV, therapeutic study.
引用
- El Beaino M, Liu J, Lewis VO, et al. Do Early Results of Proximal Humeral Allograft-Prosthetic Composite Reconstructions Persist at 5-year Followup? Clin Orthop Relat Res. 2019. PMID: 30811366. doi:10.1097/CORR.0000000000000354
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。